The Association of the British Pharmaceutical Industry has released a report suggesting that pharma companies investing in emerging start-ups is now a key source of capital for biotech innovation in the UK.
In recent years, there has been a significant increase in corporate venture capital (CVC) investment in UK biotech. The amount of capital invested in this way into UK companies increased from an average $105m per year in 2008 – 2010 and rose to $647m in 2015, a more than six-fold increase. About 60% of financing rounds in 2016 included CVC.
Image: https://www.labnews.co.uk
